α7 nicotinic acetylcholine receptors: A therapeutic target in the structure era

Current Drug Targets

Volumn 13, Issue 5, 2012, Pages 695-706

  Taly, Antoine ^a   Charon, Sébastien ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Alzheimer's disease; Schizophrenia; Tobacco dependance

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; AZD 0328; BUNGAROTOXIN RECEPTOR; DEXMECAMYLAMINE; EVP 6124; GALANTAMINE; ION CHANNEL; MEM 3454; NICOTINE; RG 3487; RO 5313534; RPI 78M; SNAKE VENOM; TC 5619; UNCLASSIFIED DRUG; VARENICLINE;

ALCOHOLISM; ALLOSTERISM; ALZHEIMER DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; BACTERIUM; BINDING SITE; BIPOLAR DISORDER; COCAINE DEPENDENCE; DRUG DESIGN; DRUG TARGETING; GENE SEQUENCE; HUMAN; MAJOR DEPRESSION; MULTIPLE SCLEROSIS; NERVE CELL; NONHUMAN; PROKARYOTE; PROTEIN INTERACTION; PROTEIN STRUCTURE; SARCOIDOSIS; SCHIZOPHRENIA; TOBACCO DEPENDENCE;

EID: 84860461624     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012800398919     Document Type: Article

References (201)

1. Changeux J-P, Edelstein SJ. Nicotinic acetylcholine receptors: from molecular biology to cognition. 1st ed. New York: Odile Jacob 2005.
2. Arneric SP, Holladay M, Williams M. Neuronal nicotinic receptors: A perspective on two decades of drug discovery research. Biochem Pharmacol 2007; 74(8): 1092-1101.
3. Levin ED, Rezvani AH. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochem Pharmacol 2007; 74(8): 1182-1191.
4. Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F. Central nicotinic receptors: structure, function, ligands, and therapeutic potential. Chem Med Chem 2007; 2(6): 746-767.
5. Taly A, Corringer PJ, Guedin D, Lestage P, Changeux JP. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 2009; 8(9): 733-750.
6. Le Novere N, Changeux JP. The Ligand Gated Ion Channel Database. Nucleic Acids Res 1999; 27(1): 340-342.
7. Gotti C, Moretti M, Gaimarri A, Zanardi A, Clementi F, Zoli M. Heterogeneity and complexity of native brain nicotinic receptors. Biochem Pharmacol 2007; 74(8): 1102-1111.
8. Grady SR, Moretti M, Zoli M, et al. Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4* subtypes mediate acetylcholine release. J Neurosci 2009; 29(7): 2272-2282.
9. Liu Q, Huang Y, Xue F, et al. A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 2009; 29(4): 918-929.
10. Gotti C, Clementi F, Fornari A, et al. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol 2009; 78(7): 703-711.
11. Picciotto MR, Caldarone BJ, Brunzell DH, Zachariou V, Stevens TR, King SL. Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. Pharmacol Ther 2001; 92(2-3): 89-108.
12. Khiroug SS, Harkness PC, Lamb PW, et al. Rat nicotinic Ach receptor alpha7 and beta2 subunits co-assemble to form functional heteromeric nicotinic receptor channels. J Physiol 2002; 540(Pt 2): 425-434.
13. Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci 1993; 13(2): 596-604.
14. Castro NG, Albuquerque EX. alpha-Bungarotoxin-sensitive hippocampal nicotinic receptor channel has a high calcium permeability. Biophys J 1995; 68(2): 516-524.
15. Sallette J, Pons S, Devillers-Thiery A, et al. Nicotine upregulates its own receptors through enhanced intracellular maturation. Neuron 2005; 46(4): 595-607.
16. Moretti M, Mugnaini M, Tessari M, et al. A comparative study of the effects of the intravenous self-administration or subcutaneous mini pump infusion of nicotine on the expression of brain neuronal nicotinic receptor subtypes. Mol Pharmacol 2010; 78(2): 287-296.
17. Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 2004; 74(6): 363-396.
18. Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 2006; 27(9): 482-491.
19. Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 2007; 47: 699-729.
20. Sharma G, Vijayaraghavan S. Nicotinic receptor signaling in nonexcitable cells. Curr Med Chem 2008; 15(28): 2921-2932.
21. Grando SA, Kist DA, Qi M, Dahl MV. Human keratinocytes synthesize, secrete, and degrade acetylcholine. J Invest Dermatol 1993; 101(1): 32-36.
22. Sastry BR, Zialkowski SE, Hansen LM, Kavanagh JP, Evoy EM. Acetylcholine release in interpeduncular nucleus following the stimulation of habenula. Brain Res 1979; 164: 334-337.
23. Gahring LC, Rogers SW. Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cells. Aaps J 2005; 7(4): 885-894.
24. Rowbotham MC, Duan WR, Thomas J, Nothaft W, Backonja MM. A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain. Pain 2009; 146(3): 245-252.
25. Egleton RD, Brown KC, Dasgupta P. Angiogenic activity of nicotinic acetylcholine receptors: implications in tobacco-related vascular diseases. Pharmacol Ther 2009; 121(2): 205-223.
26. Hogg RC, Bertrand D. Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors. Biochem Pharmacol 2007; 73(4): 459-468.
27. Ryan TJ, Grant SG. The origin and evolution of synapses. Nat Rev Neurosci 2009; 10(10): 701-712.
28. Tasneem A, Iyer LM, Jakobsson E, Aravind L. Identification of the prokaryotic ligand-gated ion channels and their implications for the mechanisms and origins of animal Cys-loop ion channels. Genome Biol 2005; 6(1): R4.
29. Bocquet N, Prado de Carvalho L, Cartaud J, et al. A prokaryotic proton-gated ion channel from the nicotinic acetylcholine receptor family. Nature 2007; 445(7123): 116-119.
30. Jones AK, Sattelle DB. The cys-loop ligand-gated ion channel superfamily of the honeybee, Apis mellifera. Invert Neurosci 2006; 6(3): 123-132.
31. Bargmann CI. Neurobiology of the Caenorhabditis elegans genome. Science 1998; 282(5396): 2028-2033.
32. Ito M, Xu H, Guffanti AA, et al. The voltage-gated Na+ channel NaVBP has a role in motility, chemotaxis, and pH homeostasis of an alkaliphilic Bacillus. Proc Natl Acad Sci USA 2004; 101(29): 10566-10571.
33. Corringer PJ, Baaden M, Bocquet N, et al. Atomic structure and dynamics of pentameric ligand-gated ion channels: new insight from bacterial homologues. J Physiol 2010; 588(Pt 4): 565-572.
34. Bocquet N, Nury H, Baaden M, et al. X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation. Nature 2009; 457(7225): 111-114.
35. Hilf RJ, Dutzler R. Structure of a potentially open state of a protonactivated pentameric ligand-gated ion channel. Nature 2009; 457(7225): 115-118.
36. Weng Y, Yang L, Corringer PJ, Sonner JM. Anesthetic sensitivity of the Gloeobacter violaceus proton-gated ion channel. Anesth Analg 2010; 110(1): 59-63.
37. Nury H, Van Renterghem C, Weng Y, et al. X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel. Nature 2011; 469(7330): 428-431.
38. Hilf RJ, Bertozzi C, Zimmermann I, Reiter A, Trauner D, Dutzler R. Structural basis of open channel block in a prokaryotic pentameric ligand-gated ion channel. Nat Struct Mol Biol 2010; 17(11): 1330-1336.
39. Hilf RJ, Dutzler R. X-ray structure of a prokaryotic pentameric ligand-gated ion channel. Nature 2008; 452(7185): 375-379.
40. Brejc K, van Dijk WJ, Klaassen RV, et al. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 2001; 411(6835): 269-276.
41. Sixma TK, Smit AB. Acetylcholine binding protein (AChBP): a secreted glial protein that provides a high-resolution model for the extracellular domain of pentameric ligand-gated ion channels. Annu Rev Biophys Biomol Struct 2003; 32: 311-334.
42. Smit AB, Syed NI, Schaap D, et al. A glia-derived acetylcholinebinding protein that modulates synaptic transmission. Nature 2001; 411(6835): 261-268.
43. Taly A, Changeux JP. Functional organization and conformational dynamics of the nicotinic receptor: a plausible structural interpretation of myasthenic mutations. Ann N Y Acad Sci 2008; 1132: 42-52.
44. Le Novere N, Grutter T, Changeux JP. Models of the extracellular domain of the nicotinic receptors and of agonist- and Ca2+-binding sites. Proc Natl Acad Sci USA 2002; 99(5): 3210-3215.
45. Hansen SB, Talley TT, Radic Z, Taylor P. Structural and ligand recognition characteristics of an acetylcholine-binding protein from Aplysia californica. J Biol Chem 2004; 279(23): 24197-24202.
46. Celie PH, Klaassen RV, van Rossum-Fikkert SE, et al. Crystal structure of acetylcholine-binding protein from Bulinus truncates reveals the conserved structural scaffold and sites of variation in nicotinic acetylcholine receptors. J Biol Chem 2005; 280(28): 26457-26466.
47. Ma Z, Huang J, Sun J, et al. A novel extrapallial fluid protein controls the morphology of nacre lamellae in the pearl oyster, Pinctada fucata. J Biol Chem 2007; 282(32): 23253-23263.
48. Hansen SB, Sulzenbacher G, Huxford T, Marchot P, Taylor P, Bourne Y. Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations. Embo J 2005; 24(20): 3635-3646.
49. Taylor P, Talley TT, Radic Z, Hansen SB, Hibbs RE, Shi J. Structure-guided drug design: conferring selectivity among neuronal nicotinic receptor and acetylcholine-binding protein subtypes. Biochem Pharmacol 2007; 74(8): 1164-1171.
50. Retra K, Geitmann M, Kool J, et al. Development of surface plasmon resonance biosensor assays for primary and secondary screening of acetylcholine binding protein ligands. Anal Biochem 2010; 407(1): 58-64.
51. Kool J, de Kloe GE, Bruyneel B, et al. Online fluorescence enhancement assay for the acetylcholine binding protein with parallel mass spectrometric identification. J Med Chem 2010; 53(12): 4720-4730.
52. Celie PH, van Rossum-Fikkert SE, van Dijk WJ, Brejc K, Smit AB, Sixma TK. Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron 2004; 41(6): 907-914.
53. Celie PH, Kasheverov IE, Mordvintsev DY, et al. Crystal structure of nicotinic acetylcholine receptor homolog AChBP in complex with an alpha-conotoxin PnIA variant. Nat Struct Mol Biol 2005; 12(7): 582-588.
54. Bourne Y, Talley TT, Hansen SB, Taylor P, Marchot P. Crystal structure of a Cbtx-AChBP complex reveals essential interactions between snake alpha-neurotoxins and nicotinic receptors. Embo J 2005; 24(8): 1512-1522.
55. Costa V, Nistri A, Cavalli A, Carloni P. A structural model of agonist binding to the alpha3beta4 neuronal nicotinic receptor. Br J Pharmacol 2003; 140(5): 921-931.
56. Iorga B, Herlem D, Barre E, Guillou C. Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the blind docking approach. J Mol Model 2006; 12(3): 366-372.
57. Grutter T, Le Novere N, Changeux JP. Rational understanding of nicotinic receptors drug binding. Curr Top Med Chem 2004; 4(6): 645-650.
58. Henchman RH, Wang HL, Sine SM, Taylor P, McCammon JA. Ligand-induced conformational change in the alpha7 nicotinic receptor ligand binding domain. Biophys J 2005; 88(4): 2564-2576.
59. Law RJ, Henchman RH, McCammon JA. A gating mechanism proposed from a simulation of a human alpha7 nicotinic acetylcholine receptor. Proc Natl Acad Sci USA 2005; 102(19): 6813-6818.
60. Xu Y, Barrantes FJ, Luo X, Chen K, Shen J, Jiang H. Conformational dynamics of the nicotinic acetylcholine receptor channel: a 35-ns molecular dynamics simulation study. J Am Chem Soc 2005; 127(4): 1291-1299.
61. Schapira M, Abagyan R, Totrov M. Structural model of nicotinic acetylcholine receptor isotypes bound to acetylcholine and nicotine. BMC Struct Biol 2002; 2: 1.
62. Sine SM. The nicotinic receptor ligand binding domain. J Neurobiol 2002; 53(4): 431-446.
63. Huang X, Zheng F, Stokes C, Papke RL, Zhan CG. Modeling binding modes of alpha7 nicotinic acetylcholine receptor with ligands: the roles of Gln117 and other residues of the receptor in agonist binding. J Med Chem 2008; 51(20): 6293-6302.
64. Toshima K, Kanaoka S, Yamada A, et al. Combined roles of loops C and D in the interactions of a neonicotinoid insecticide imidacloprid with the alpha4beta2 nicotinic acetylcholine receptor. Neuropharmacology 2009; 56(1): 264-272.
65. Luttmann E, Ludwig J, Hoffle-Maas A, Samochocki M, Maelicke A, Fels G. Structural model for the binding sites of allosterically potentiating ligands on nicotinic acetylcholine receptors. Chem Med Chem 2009; 4(11): 1874-1882.
66. Turabekova MA, Rasulev BF, Dzhakhangirov FN, Leszczynska D, Leszczynski J. Aconitum and Delphinium alkaloids of curare-like activity. QSAR analysis and molecular docking of alkaloids into AChBP. Eur J Med Chem 2010; 45(9): 3885-3894.
67. Gao F, Bern N, Little A, et al. Curariform antagonists bind in different orientations to acetylcholine-binding protein. J Biol Chem 2003; 278(25): 23020-23026.
68. Abin-Carriquiry JA, Zunini MP, Cassels BK, Wonnacott S, Dajas F. In silico characterization of cytisinoids docked into an acetylcholine binding protein. Bioorg Med Chem Lett 2010; 20(12): 3683-3687.
69. Slavov SH, Radzvilovits M, LeFrancois S, et al. A computational study of the binding of 3-(arylidene) anabaseines to two major brain nicotinic acetylcholine receptors and to the acetylcholine binding protein. Eur J Med Chem 2010; 45(6): 2433-2446.
70. Utsintong M, Talley TT, Taylor PW, Olson AJ, Vajragupta O. Virtual screening against alpha-cobratoxin. J Biomol Screen 2009; 14(9): 1109-1118.
71. Babakhani A, Talley TT, Taylor P, McCammon JA. A virtual screening study of the acetylcholine binding protein using a relaxed-complex approach. Comput Biol Chem 2009; 33(2): 160-170.
72. Ulens C, Akdemir A, Jongejan A, et al. Use of acetylcholine binding protein in the search for novel alpha7 nicotinic receptor ligands. In silico docking, pharmacological screening, and X-ray analysis. J Med Chem 2009; 52(8): 2372-2383.
73. Artali R, Bombieri G, Meneghetti F. Docking of 6-chloropyridazin-3-yl derivatives active on nicotinic acetylcholine receptors into molluscan acetylcholine binding protein (AChBP). Farmaco 2005; 60(4): 313-320.
74. Sine SM, Wang HL, Gao F. Toward atomic-scale understanding of ligand recognition in the muscle nicotinic receptor. Curr Med Chem 2004; 11(5): 559-567.
75. Konstantakaki M, Changeux J, Taly A. Docking of long chain alpha-cobratoxin suggests a basal state conformation of the nicotinic receptor. Biochem Biophys Res Commun 2007; 359(3): 413-418.
76. Haddadian EJ, Cheng MH, Coalson RD, Xu Y, Tang P. In silico models for the human alpha4beta2 nicotinic acetylcholine receptor. J Phys Chem B 2008; 112(44): 13981-13990.
77. Huang X, Zheng F, Zhan CG. Modeling differential binding of alpha4beta2 nicotinic acetylcholine receptor with agonists and antagonists. J Am Chem Soc 2008; 130(49): 16691-16696.
78. Hucho F, Changeux JP. Molecular weight and quaternary structure of the cholinergic receptor protein extracted by detergents from Electrophorus electricus electric tissue. FEBS Lett 1973; 38(1): 11-15.
79. Cartaud J, Benedetti EL, Cohen JB, Meunier JC, Changeux JP. Presence of a lattice structure in membrane fragments rich in nicotinic receptor protein from the electric organ of Torpedo marmorata. FEBS Lett 1973; 33(1): 109-113.
80. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J Mol Biol 2005; 346(4): 967-989.
81. Dellisanti CD, Yao Y, Stroud JC, Wang ZZ, Chen L. Crystal structure of the extracellular domain of nAChR alpha1 bound to alpha-bungarotoxin at 1.94 A resolution. Nat Neurosci 2007; 10(8): 953-962.
82. Miyazawa A, Fujiyoshi Y, Unwin N. Structure and gating mechanism of the acetylcholine receptor pore. Nature 2003; 423(6943): 949-955.
83. Blanton MP, Cohen JB. Identifying the lipid-protein interface of the Torpedo nicotinic acetylcholine receptor: secondary structure implications. Biochemistry 1994; 33(10): 2859-2872.
84. Jansen M, Bali M, Akabas MH. Modular design of Cys-loop ligand-gated ion channels: functional 5-HT3 and GABA rho1 receptors lacking the large cytoplasmic M3M4 loop. J Gen Physiol 2008; 131(2): 137-146.
85. Corringer PJ, Galzi JL, Eisele JL, Bertrand S, Changeux JP, Bertrand D. Identification of a new component of the agonist binding site of the nicotinic alpha 7 homooligomeric receptor. J Biol Chem 1995; 270(20): 11749-11752.
86. Changeux JP, Podleski TR, Wofsy L. Affinity labeling of the acetylcholine-receptor. Proc Natl Acad Sci USA 1967; 58(5): 2063-2070.
87. Corringer PJ, Le Novere N, Changeux JP. Nicotinic receptors at the amino acid level. Annu Rev Pharmacol Toxicol 2000; 40: 431-458.
88. Grutter T, Changeux JP. Nicotinic receptors in wonderland. Trends Biochem Sci 2001; 26(8): 459-463.
89. Mourot A, Grutter T, Goeldner M, Kotzyba-Hibert F. Dynamic structural investigations on the torpedo nicotinic acetylcholine receptor by time-resolved photoaffinity labeling. Chembiochem 2006; 7(4): 570-583.
90. Kotzyba-Hibert F, Mourot A, Grutter T, Goeldner M, Eds. XIth Cholinergic Mechanisms Symposium. London: Taylor & Francis 2004.
91. Kalamida D, Poulas K, Avramopoulou V, et al. Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. Febs J 2007; 274(15): 3799-3845.
92. Brejc K, van Dijk WJ, Smit AB, Sixma TK. The 2.7 A structure of AChBP, homologue of the ligand-binding domain of the nicotinic acetylcholine receptor. Novartis Found Symp 2002; 245: 22-29; discussion 9-32, 165-8.
93. Hansen SB, Sulzenbacher G, Huxford T, Marchot P, Bourne Y, Taylor P. Structural characterization of agonist and antagonistbound acetylcholine-binding protein from Aplysia californica. J Mol Neurosci 2006; 30(1-2): 101-102.
94. Hansen SB, Taylor P. Galanthamine and non-competitive inhibitor binding to ACh-binding protein: evidence for a binding site on nonalpha-subunit interfaces of heteromeric neuronal nicotinic receptors. J Mol Biol 2007; 369(4): 895-901.
95. Ihara M, Okajima T, Yamashita A, et al. Crystal structures of Lymnaea stagnalis AChBP in complex with neonicotinoid insecticides imidacloprid and clothianidin. Invert Neurosci 2008; 8(2): 71-81.
96. Dennis M, Giraudat J, Kotzyba-Hibert F, et al. Amino acids of the Torpedo marmorata acetylcholine receptor alpha subunit labeled by a photoaffinity ligand for the acetylcholine binding site. Biochemistry 1988; 27(7): 2346-2357.
97. Galzi JL, Revah F, Black D, Goeldner M, Hirth C, Changeux JP. Identification of a novel amino acid alpha-tyrosine 93 within the cholinergic ligands-binding sites of the acetylcholine receptor by photoaffinity labeling. Additional evidence for a three-loop model of the cholinergic ligands-binding sites. J Biol Chem 1990; 265(18): 10430-10437.
98. Dougherty DA, Stauffer DA. Acetylcholine binding by a synthetic receptor: implications for biological recognition. Science 1990; 250(4987): 1558-1560.
99. Glennon RA, Dukat M. Central nicotinic receptor ligands and pharmacophores. Pharm Acta Helv 2000; 74(2-3): 103-114.
100. Glennon RA, Dukat M, Liao L. Musings on alpha4beta2 nicotinic acetylcholine (nACh) receptor pharmacophore models. Curr Top Med Chem 2004; 4(6): 631-644.
101. Zhong W, Gallivan JP, Zhang Y, Li L, Lester HA, Dougherty DA. From ab initio quantum mechanics to molecular neurobiology: a cation-pi binding site in the nicotinic receptor. Proc Natl Acad Sci USA 1998; 95(21): 12088-12093.
102. Williamson PT, Verhoeven A, Miller KW, Meier BH, Watts A. The conformation of acetylcholine at its target site in the membrane-embedded nicotinic acetylcholine receptor. Proc Natl Acad Sci USA 2007; 104(46): 18031-18036.
103. Xiu X, Puskar NL, Shanata JA, Lester HA, Dougherty DA. Nicotine binding to brain receptors requires a strong cation-pi interaction. Nature 2009; 458(7237): 534-537.
104. Blum AP, Lester HA, Dougherty DA. Inaugural article: Nicotinic pharmacophore: the pyridine N of nicotine and carbonyl of acetylcholine hydrogen bond across a subunit interface to a backbone NH. Proc Natl Acad Sci USA 2010; 107(30): 13206-13211.
105. Ulens C, Hogg RC, Celie PH, et al. Structural determinants of selective alpha-conotoxin binding to a nicotinic acetylcholine receptor homolog AChBP. Proc Natl Acad Sci USA 2006; 103(10): 3615-3620.
106. Giraudat J, Dennis M, Heidmann T, Chang JY, Changeux JP. Structure of the high-affinity binding site for noncompetitive blockers of the acetylcholine receptor: serine-262 of the delta subunit is labeled by [3H]chlorpromazine. Proc Natl Acad Sci USA 1986; 83(8): 2719-2723.
107. Hucho F, Oberthur W, Lottspeich F. The ion channel of the nicotinic acetylcholine receptor is formed by the homologous helices M II of the receptor subunits. FEBS Lett 1986; 205(1): 137-142.
108. Faghih R, Gopalakrishnan M, Briggs CA. Allosteric modulators of the alpha7 nicotinic acetylcholine receptor. J Med Chem 2008; 51(4): 701-712.
109. Bertrand D, Gopalakrishnan M. Allosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol 2007; 74: 1155-1163.
110. Arias HR, Bhumireddy P, Bouzat C. Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors. Int J Biochem Cell Biol 2006; 38(8): 1254-1276.
111. Changeux JP, Taly A. Nicotinic receptors, allosteric proteins and medicine. Trends Mol Med 2008; 14(3): 93-102.
112. Monod J, Wyman J, Changeux JP. On the nature of allosteric transitions: a plausible model. J Mol Biol 1965; 12: 88-118.
113. Changeux JP, Edelstein SJ. Allosteric mechanisms of signal transduction. Science 2005; 308(5727): 1424-1428.
114. Grosman C, Auerbach A. Kinetic, mechanistic, and structural aspects of unliganded gating of acetylcholine receptor channels: a single-channel study of second transmembrane segment 12' mutants. J Gen Physiol 2000; 115(5): 621-635.
115. Lange OF, Lakomek NA, Fares C, et al. Recognition dynamics up to microseconds revealed from an RDC-derived ubiquitin ensemble in solution. Science 2008; 320(5882): 1471-1475.
116. Tobi D, Bahar I. Structural changes involved in protein binding correlate with intrinsic motions of proteins in the unbound state. Proc Natl Acad Sci USA 2005; 102(52): 18908-18913.
117. Cui Q, Karplus M. Allostery and cooperativity revisited. Protein Sci 2008; 17(8): 1295-1307.
118. Purohit P, Auerbach A. Energetics of gating at the apoacetylcholine receptor transmitter binding site. J Gen Physiol 2010; 135(4): 321-331.
119. Katz B, Thesleff S. A study of the desensitization produced by acetylcholine at the motor end-plate. J Physiol 1957; 138(1): 63-80.
120. Baenziger JE, Corringer PJ. 3D structure and allosteric modulation of the transmembrane domain of pentameric ligand-gated ion channels. Neuropharmacology 2011; 60(1): 116-125.
121. daCosta CJ, Baenziger JE. A lipid-dependent uncoupled conformation of the acetylcholine receptor. J Biol Chem 2009; 284(26): 17819-17825.
122. Lape R, Colquhoun D, Sivilotti LG. On the nature of partial agonism in the nicotinic receptor superfamily. Nature 2008; 454(7205): 722-727.
123. Mukhtasimova N, Lee WY, Wang HL, Sine SM. Detection and trapping of intermediate states priming nicotinic receptor channel opening. Nature 2009; 459(7245): 451-454.
124. Bouzat C, Bartos M, Corradi J, Sine SM. The interface between extracellular and transmembrane domains of homomeric Cys-loop receptors governs open-channel lifetime and rate of desensitization. J Neurosci 2008; 28(31): 7808-7819.
125. White BH, Cohen JB. Agonist-induced changes in the structure of the acetylcholine receptor M2 regions revealed by photoincorporation of an uncharged nicotinic noncompetitive antagonist. J Biol Chem 1992; 267(22): 15770-15783.
126. Blanton MP, McCardy EA, Huggins A, Parikh D. Probing the structure of the nicotinic acetylcholine receptor with the hydrophobic photoreactive probes [125I]TID-BE and [125I]TIDPC/16. Biochemistry 1998; 37(41): 14545-14555.
127. Taly A, Delarue M, Grutter T, et al. Normal mode analysis suggests a quaternary twist model for the nicotinic receptor gating mechanism. Biophys J 2005; 88(6): 3954-3965.
128. Dutertre S, Lewis RJ. Toxin insights into nicotinic acetylcholine receptors. Biochem Pharmacol 2006; 72(6): 661-670.
129. Hibbs RE, Sulzenbacher G, Shi J, et al. Structural determinants for interaction of partial agonists with acetylcholine binding protein and neuronal alpha7 nicotinic acetylcholine receptor. Embo J 2009; 28(19): 3040-3051.
130. Bourne Y, Radic Z, Araoz R, et al. Structural determinants in phycotoxins and AChBP conferring high affinity binding and nicotinic AChR antagonism. Proc Natl Acad Sci USA 2010; 107(13): 6076-6081.
131. Fruchart-Gaillard C, Gilquin B, Antil-Delbeke S, et al. Experimentally based model of a complex between a snake toxin and the alpha 7 nicotinic receptor. Proc Natl Acad Sci USA 2002; 99(5): 3216-3221.
132. Dellisanti CD, Hanson SM, Chen L, Czajkowski C. Packing of the extracellular domain hydrophobic core has evolved to facilitate pentameric ligand-gated ion channel function. J Biol Chem 2011; 286(5): 3658-3670.
133. Taly A, Corringer PJ, Grutter T, de Carvalho LP, Karplus M, Changeux JP. Implications of the quaternary twist allosteric model for the physiology and pathology of nicotinic acetylcholine receptors. Proc Natl Acad Sci USA 2006; 103(45): 16965-16970.
134. Samson AO, Levitt M. Inhibition mechanism of the acetylcholine receptor by alpha-neurotoxins as revealed by normal-mode dynamics. Biochemistry 2008; 47(13): 4065-4070.
135. Yi M, Tjong H, Zhou HX. Spontaneous conformational change and toxin binding in alpha7 acetylcholine receptor: insight into channel activation and inhibition. Proc Natl Acad Sci USA 2008; 105(24): 8280-8285.
136. Cheng X, Wang H, Grant B, Sine SM, McCammon JA. Targeted molecular dynamics study of c-loop closure and channel gating in nicotinic receptors. PLoS Comput Biol 2006; 2(9): e134.
137. Liu X, Xu Y, Li H, Wang X, Jiang H, Barrantes FJ. Mechanics of channel gating of the nicotinic acetylcholine receptor. PLoS Comput Biol 2008; 4(1): e19.
138. Corriveau RA, Romano SJ, Conroy WG, Oliva L, Berg DK. Expression of neuronal acetylcholine receptor genes in vertebrate skeletal muscle during development. J Neurosci 1995; 15(2): 1372-1383.
139. Romano SJ, Pugh PC, McIntosh JM, Berg DK. Neuronal-type acetylcholine receptors and regulation of alpha 7 gene expression in vertebrate skeletal muscle. J Neurobiol 1997; 32(1): 69-80.
140. Fischer U, Reinhardt S, Albuquerque EX, Maelicke A. Expression of functional alpha7 nicotinic acetylcholine receptor during mammalian muscle development and denervation. Eur J Neurosci 1999; 11(8): 2856-2864.
141. Bruggmann D, Lips KS, Pfeil U, Haberberger RV, Kummer W. Rat arteries contain multiple nicotinic acetylcholine receptor alphasubunits. Life Sci 2003; 72(18-19): 2095-2099.
142. Macklin KD, Maus AD, Pereira EF, Albuquerque EX, Conti-Fine BM. Human vascular endothelial cells express functional nicotinic acetylcholine receptors. J Pharmacol Exp Ther 1998; 287(1): 435-439.
143. Skok MV. Non-neuronal nicotinic acetylcholine receptors: cholinergic regulation of the immune processes. Neurophysiology 2007; 39(4/5): 307-314.
144. Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the nonneuronal cholinergic system in humans. Br J Pharmacol 2008; 154(8): 1558-1571.
145. Skok MV, Kalashnik EN, Koval LN, et al. Functional nicotinic acetylcholine receptors are expressed in B lymphocyte-derived cell lines. Mol Pharmacol 2003; 64(4): 885-889.
146. Skok MV, Grailhe R, Agenes F, Changeux JP. The role of nicotinic receptors in B-lymphocyte development and activation. Life Sci 2007; 80(24-25): 2334-2336.
147. Sharma G, Vijayaraghavan S. Nicotinic receptor signaling in nonexcitable cells. J Neurobiol 2002; 53(4): 524-534.
148. Cooke JP, Bitterman H. Nicotine and angiogenesis: a new paradigm for tobacco-related diseases. Ann Med 2004; 36(1): 33-40.
149. Cooke JP. Angiogenesis and the role of the endothelial nicotinic acetylcholine receptor. Life Sci 2007; 80(24-25): 2347-2351.
150. Fujii T, Takada-Takatori Y, Kawashima K. Basic and clinical aspects of non-neuronal acetylcholine: expression of an independent, non-neuronal cholinergic system in lymphocytes and its clinical significance in immunotherapy. J Pharmacol Sci 2008; 106(2): 186-192.
151. Middlebrook AJ, Martina C, Chang Y, Lukas RJ, DeLuca D. Effects of nicotine exposure on T cell development in fetal thymus organ culture: arrest of T cell maturation. J Immunol 2002; 169(6): 2915-2924.
152. Richman DP, Arnason BG. Nicotinic acetylcholine receptor: evidence for a functionally distinct receptor on human lymphocytes. Proc Natl Acad Sci USA 1979; 76(9): 4632-4635.
153. Rinner I, Kukulansky T, Felsner P, et al. Cholinergic stimulation modulates apoptosis and differentiation of murine thymocytes via a nicotinic effect on thymic epithelium. Biochem Biophys Res Commun 1994; 203(2): 1057-1062.
154. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003; 421(6921): 384-388.
155. van Maanen MA, Vervoordeldonk MJ, Tak PP. The cholinergic anti-inflammatory pathway: towards innovative treatment of rheumatoid arthritis. Nature Rev Rheumatol 2009; 5: 229-232.
156. Shytle RD, Mori T, Townsend K, et al. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 2004; 89(2): 337-343.
157. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405(6785): 458-462.
158. Osborne-Hereford AV, Rogers SW, Gahring LC. Neuronal nicotinic alpha7 receptors modulate inflammatory cytokine production in the skin following ultraviolet radiation. J Neuroimmunol 2008; 193(1-2): 130-139.
159. Gahring LC, Osborne AV, Reed M, Rogers SW. Neuronal nicotinic alpha7 receptors modulate early neutrophil infiltration to sites of skin inflammation. J Neuroinflammation 2010; 7(1): 38.
160. Grando SA, Horton RM, Pereira EF, et al. A nicotinic acetylcholine receptor regulating cell adhesion and motility is expressed in human keratinocytes. J Invest Dermatol 1995; 105(6): 774-781.
161. Grando SA, Horton RM, Mauro TM, Kist DA, Lee TX, Dahl MV. Activation of keratinocyte nicotinic cholinergic receptors stimulates calcium influx and enhances cell differentiation. J Invest Dermatol 1996; 107(3): 412-418.
162. Grando SA. Biological functions of keratinocyte cholinergic receptors. J Investig Dermatol Symp Proc 1997; 2(1): 41-48.
163. Arredondo J, Nguyen VT, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA. A receptor-mediated mechanism of nicotine toxicity in oral keratinocytes. Lab Invest 2001; 81(12): 1653-1668.
164. Nguyen VT, Chernyavsky AI, Arredondo J, et al. Synergistic control of keratinocyte adhesion through muscarinic and nicotinic acetylcholine receptor subtypes. Exp Cell Res 2004; 294(2): 534-549.
165. Zia S, Ndoye A, Lee TX, Webber RJ, Grando SA. Receptormediated inhibition of keratinocyte migration by nicotine involves modulations of calcium influx and intracellular concentration. J Pharmacol Exp Ther 2000; 293(3): 973-981.
166. Kindt F, Wiegand S, Niemeier V, et al. Reduced expression of nicotinic alpha subunits 3, 7, 9 and 10 in lesional and nonlesional atopic dermatitis skin but enhanced expression of alpha subunits 3 and 5 in mast cells. Br J Dermatol 2008; 159(4): 847-857.
167. Kurzen H, Berger H, Jager C, et al. Phenotypical and molecular profiling of the extraneuronal cholinergic system of the skin. J Invest Dermatol 2004; 123(5): 937-949.
168. Arredondo J, Nguyen VT, Chernyavsky AI, et al. Functional role of alpha7 nicotinic receptor in physiological control of cutaneous homeostasis. Life Sci 2003; 72(18-19): 2063-2067.
169. Grando SA. Cholinergic control of epidermal cohesion. Exp Dermatol 2006; 15(4): 265-282.
170. Chimienti F, Hogg RC, Plantard L, et al. Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda. Hum Mol Genet 2003; 12(22): 3017-3024.
171. Arredondo J, Chernyavsky AI, Webber RJ, Grando SA. Biological effects of SLURP-1 on human keratinocytes. J Invest Dermatol 2005; 125(6): 1236-1241.
172. Kurzen H, Henrich C, Booken D, et al. Functional characterization of the epidermal cholinergic system in vitro. J Invest Dermatol 2006; 126(11): 2458-2472.
173. Maus AD, Pereira EF, Karachunski PI, et al. Human and rodent bronchial epithelial cells express functional nicotinic acetylcholine receptors. Mol Pharmacol 1998; 54(5): 779-788.
174. Wang Y, Pereira EF, Maus AD, et al. Human bronchial epithelial and endothelial cells express alpha7 nicotinic acetylcholine receptors. Mol Pharmacol 2001; 60(6): 1201-1209.
175. Fu XW, Lindstrom J, Spindel ER. Nicotine activates and up regulates nicotinic acetylcholine receptors in bronchial epithelial cells. Am J Respir Cell Mol Biol 2009; 41(1): 93-99.
176. Klapproth H, Racke K, Wessler I. Acetylcholine and nicotine stimulate the release of granulocyte-macrophage colony stimulating factor from cultured human bronchial epithelial cells. Naunyn Schmiedebergs Arch Pharmacol 1998; 357(4): 472-475.
177. Schuller HM, Plummer HK, 3rd, Jull BA. Receptor-mediated effects of nicotine and its nitrosated derivative NNK on pulmonary neuroendocrine cells. Anat Rec A Discov Mol Cell Evol Biol 2003; 270(1): 51-58.
178. Song P, Sekhon HS, Jia Y, et al. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res 2003; 63(1): 214-221.
179. Cunningham JM, Lennon VA, Lambert EH, Scheithauer B. Acetylcholine receptors in small cell carcinomas. J Neurochem 1985; 45(1): 159-167.
180. Cattaneo MG, Codignola A, Vicentini LM, Clementi F, Sher E. Nicotine stimulates a serotonergic autocrine loop in human smallcell lung carcinoma. Cancer Res 1993; 53(22): 5566-5568.
181. Quik M, Chan J, Patrick J. alpha-Bungarotoxin blocks the nicotinic receptor mediated increase in cell number in a neuroendocrine cell line. Brain Res 1994; 655(1-2): 161-167.
182. Maneckjee R, Minna JD. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci USA 1990; 87(9): 3294-3298.
183. Paleari L, Cesario A, Fini M, Russo P. alpha7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma? Drug Discov Today 2009; 14(17-18): 822-836.
184. Lam DC, Girard L, Ramirez R, et al. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res 2007; 67(10): 4638-4647.
185. Paleari L, Negri E, Catassi A, et al. Inhibition of nonneuronal alpha7-nicotinic receptor for lung cancer treatment. Am J Respir Crit Care Med 2009; 179(12): 1141-1150.
186. Conti-Tronconi BM, McLane KE, Raftery MA, Grando SA, Protti MP. The nicotinic acetylcholine receptor: structure and autoimmune pathology. Crit Rev Biochem Mol Biol 1994; 29(2): 69-123.
187. Heeschen C, Jang JJ, Weis M, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001; 7(7): 833-839.
188. Heeschen C, Weis M, Aicher A, Dimmeler S, Cooke JP. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest 2002; 110(4): 527-536.
189. Heeschen C, Weis M, Cooke JP. Nicotine promotes arteriogenesis. J Am Coll Cardiol 2003; 41(3): 489-496.
190. Dasgupta P, Rastogi S, Pillai S, et al. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 2006; 116(8): 2208-2217.
191. Dasgupta P, Chellappan SP. Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story. Cell Cycle 2006; 5(20): 2324-2328.
192. Arias HR, Richards VE, Ng D, Ghafoori ME, Le V, Mousa SA. Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis. Int J Biochem Cell Biol 2009; 41(7): 1441-1451.
193. Dom AM, Buckley AW, Brown KC, et al. The {alpha}7-nicotinic acetylcholine receptor and MMP-2/9 pathway mediate the proangiogenic effect of nicotine in human retinal endothelial cells. Invest Ophthalmol Vis Sci 2011; 52(7): 4428-4438.
194. Wu JC, Chruscinski A, De Jesus Perez VA, et al. Cholinergic modulation of angiogenesis: role of the 7 nicotinic acetylcholine receptor. J Cell Biochem 2009; 108(2): 433-446.
195. Li XW, Wang H. Non-neuronal nicotinic alpha 7 receptor, a new endothelial target for revascularization. Life Sci 2006; 78(16): 1863-1870.
196. Abbruscato TJ, Lopez SP, Mark KS, Hawkins BT, Davis TP. Nicotine and cotinine modulate cerebral microvascular permeability and protein expression of ZO-1 through nicotinic acetylcholine receptors expressed on brain endothelial cells. J Pharm Sci 2002; 91(12): 2525-2538.
197. Hawkins BT, Egleton RD, Davis TP. Modulation of cerebral microvascular permeability by endothelial nicotinic acetylcholine receptors. Am J Physiol Heart Circ Physiol 2005; 289(1): H212-H219.
198. Hosli L, Hosli E, Della Briotta G, Quadri L, Heuss L. Action of acetylcholine, muscarine, nicotine and antagonists on the membrane potential of astrocytes in cultured rat brainstem and spinal cord. Neurosci Lett 1988; 92(2): 165-170.
199. Graham AJ, Ray MA, Perry EK, et al. Differential nicotinic acetylcholine receptor subunit expression in the human hippocampus. J Chem Neuroanat 2003; 25(2): 97-113.
200. De Simone R, Ajmone-Cat MA, Carnevale D, Minghetti L. Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuro inflammation 2005; 2(1): 4.
201. Suzuki T, Hide I, Matsubara A, et al. Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuro protective role. J Neurosci Res 2006; 83(8): 1461-1470.